Prescriptions for Spravato, which is psychedelic-based drug made by Johnson & Johnson, are booming and new clinics are opening that specialize in administering it, Peter Loftus of The Wall Street Journal reports. Sales are rising so much that Spravato is now a key part of the company’s lineup and analysts expect the drug to surpass $1B in annual sales this year. Spravatos’ upward trajectory demonstrates the challenges and opportunities for the use of the drugs in mental health.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on JNJ:
- Kenvue (KVUE) Under Pressure after Activist Investor Starboard Acquires Stake
- Johnson & Johnson treatment of acute myeloid leukemia granted orphan status
- Is Johnson & Johnson (NYSE:JNJ) a Worthwhile Dividend Stock?
- Johnson & Johnson price target lowered to $159 from $162 at Goldman Sachs
- Johnson & Johnson price target raised to $181 from $178 at RBC Capital
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
